Leading venture firms and research institutions launched the European Life Science Coalition to mobilize private and public capital for the continent’s biotech sector. Members managing over €24 billion aim to address structural barriers—fragmented capital markets, slow late‑stage financing and limited IPO exits in Europe—that have driven startups to list in the U.S. The coalition will lobby for policy changes, speedier clinical trial processes, and mechanisms to attract institutional investors. Founding voices include Sofinnova and Forbion; spokespeople emphasized the need to keep European innovation and jobs onshore as the industry globalizes.